{
  "docId": "019de070-cb6f-702e-8ba7-38c2ee57750d",
  "docSlug": "70846fe5de6d20355c3868d80f4845b0",
  "documentTitle": "BioNTech | Results Presentation Deck | 36 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 36,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The diagram uses a staircase visual for dose levels and horizontal arrows for expansion cohorts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-cb6f-702e-8ba7-38c2ee57750d/25",
  "deckHref": "/decks/019de070-cb6f-702e-8ba7-38c2ee57750d",
  "deckJsonHref": "/decks/019de070-cb6f-702e-8ba7-38c2ee57750d.json",
  "deckAnchorHref": "/decks/019de070-cb6f-702e-8ba7-38c2ee57750d#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.92,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Part 1: Monotherapy Dose Escalation to Part 2: Combination Therapy Expansions",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bccafb2c-56c3-4931-8772-9c2055ba3ece",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.65,
        "x": 0.1,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "NSCLC, Non-small Cell Lung Cancer; DL, dose level; MTD, maximum tolerated dose; RP2D, recommended Phase 2 dose; G2, grade 2; DLT, dose limiting toxicity; SoC, Standard of Care; SCCHN, Squamous cell carcinoma of the head and neck; HCC, Hepatocellular carcinoma; RCC, Renal cell carcinoma; TNBC, Triple-negative breast cancer; CPI; checkpoint inhibitor",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7d872b4-e761-4eea-9b02-b7aafa30ab38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.92,
        "x": 0.04,
        "y": 0.75
      },
      "kind": "subtitle",
      "text": "Evaluation of dose escalation, safety, pharmacokinetics and pharmacodynamics of BNT151 with expansion cohorts in multiple solid tumor indications",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a40f02b-f176-4477-82e4-ea3f2cd2bfb4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "BNT151-01 Open-label, multicenter Phase 1/2a, first-in-human trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "edc0ac5c-018a-4ee5-a6a7-c4e2762f9db8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}